Understanding SOCS3 inhibition of JAK activity in myeloproliferative disorders

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1011804

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The myeloproliferative disorders are diseases in which abnormal blood cell development leads to a risk of stroke, thrombosis, hemorrhage and leukemia. Remarkably, three of these disorders are caused by an error in a single enzyme that makes it over active. The enzyme, JAK2, controls how cells respond to hormone-like messengers called cytokines. We are investigating a cellular pathway that inhibits this enzyme in order to understand the progression and potential treatment of the disorders.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: Project Grants

Funding Amount: $524,820.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Signal Transduction

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

JAK/STAT pathway | cytokine signalling | haematological disorders | haematological malignancy | haematopoiesis | kinase inhibitors | proliferative disorders | suppressor of cytokine signalling (SOCS) | ubiquitination

Related Links